New micronized crystalline form-R of tafamidis used for treatment of cardiomyopathy of wild type or hereditary transthyretin- mediated amyloidosis in adults
	BALRAJU K; REDDY S R; RAJAN S T
	2023-08-11
专利权人	MSN LAB PRIVATE LTD R & D CENT (MSNM-Non-standard)
申请日期	2023-08-11
专利号	IN202341054113-A
成果简介	NOVELTY - Micronized crystalline form-R of tafamidis, is new. USE - Micronized crystalline form-R of tafamidis used for the treatment of the cardiomyopathy of wild type or hereditary transthyretin- mediated amyloidosis in adults. No biological data is given. ADVANTAGE - The micronized crystalline form-R of tafamidis reduced the cardiovascular mortality and cardiovascular-related hospitalization. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing of the micronized crystalline form-R of tafamidis.
IPC 分类号	A61K-031/423 ; C07D-263/57
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20875
专题	中国科学院新疆生态与地理研究所
作者单位	MSN LAB PRIVATE LTD R & D CENT (MSNM-Non-standard)
推荐引用方式 GB/T 7714	BALRAJU K,REDDY S R,RAJAN S T. New micronized crystalline form-R of tafamidis used for treatment of cardiomyopathy of wild type or hereditary transthyretin- mediated amyloidosis in adults. IN202341054113-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。